-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Large Drop in Short Interest
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Large Drop in Short Interest
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 36,800 shares, a decrease of 16.0% from the November 15th total of 43,800 shares. Currently, 0.4% of the company's stock are sold short. Based on an average daily trading volume, of 36,900 shares, the days-to-cover ratio is presently 1.0 days.
Analyst Ratings Changes
CADL has been the subject of several recent research reports. HC Wainwright initiated coverage on Candel Therapeutics in a report on Friday, December 2nd. They set a "buy" rating and a $11.00 price target for the company. Credit Suisse Group decreased their price target on Candel Therapeutics from $10.00 to $8.00 and set an "outperform" rating for the company in a report on Wednesday, December 7th.
Get Candel Therapeutics alerts:Candel Therapeutics Stock Performance
NASDAQ:CADL traded down $0.24 during trading on Friday, reaching $1.65. The company's stock had a trading volume of 145,640 shares, compared to its average volume of 35,939. The firm has a market cap of $47.68 million, a price-to-earnings ratio of -3.93 and a beta of 0.18. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.41 and a current ratio of 13.41. The firm has a 50 day moving average of $1.92 and a 200-day moving average of $2.89. Candel Therapeutics has a 12 month low of $1.47 and a 12 month high of $8.70.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in CADL. Citadel Advisors LLC purchased a new position in shares of Candel Therapeutics during the 3rd quarter valued at $53,000. BlackRock Inc. lifted its position in shares of Candel Therapeutics by 15.5% during the 1st quarter. BlackRock Inc. now owns 132,322 shares of the company's stock valued at $674,000 after buying an additional 17,708 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Candel Therapeutics during the 2nd quarter valued at $2,408,000. Hedge funds and other institutional investors own 21.97% of the company's stock.About Candel Therapeutics
(Get Rating)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Further Reading
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 36,800 shares, a decrease of 16.0% from the November 15th total of 43,800 shares. Currently, 0.4% of the company's stock are sold short. Based on an average daily trading volume, of 36,900 shares, the days-to-cover ratio is presently 1.0 days.
坎德尔治疗公司(纳斯达克代码：CADL-GET评级)是11月份空头股数大幅下降的目标。截至11月30日，空头股数共有3.68万股，较11月15日的4.38万股减少16.0%。目前，该公司0.4%的股票被卖空。以日均成交量36,900股计算，目前天数与回补比率为1.0天。
Analyst Ratings Changes
分析师评级发生变化
CADL has been the subject of several recent research reports. HC Wainwright initiated coverage on Candel Therapeutics in a report on Friday, December 2nd. They set a "buy" rating and a $11.00 price target for the company. Credit Suisse Group decreased their price target on Candel Therapeutics from $10.00 to $8.00 and set an "outperform" rating for the company in a report on Wednesday, December 7th.
CADL是最近几份研究报告的主题。HC Wainwright在12月2日星期五的一份报告中开始了对Candel治疗公司的报道。他们为该公司设定了“买入”评级和11.00美元的目标价。瑞士信贷集团将Candel Treeutics的目标价从10.00美元下调至8.00美元，并在12月7日星期三的一份报告中为该公司设定了“跑赢大盘”的评级。
Candel Therapeutics Stock Performance
Candel Treeutics股票表现
NASDAQ:CADL traded down $0.24 during trading on Friday, reaching $1.65. The company's stock had a trading volume of 145,640 shares, compared to its average volume of 35,939. The firm has a market cap of $47.68 million, a price-to-earnings ratio of -3.93 and a beta of 0.18. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.41 and a current ratio of 13.41. The firm has a 50 day moving average of $1.92 and a 200-day moving average of $2.89. Candel Therapeutics has a 12 month low of $1.47 and a 12 month high of $8.70.
纳斯达克：CADL在周五的交易中下跌0.24美元，至1.65美元。该公司股票的成交量为145,640股，而其平均成交量为35,939股。该公司市值为4768万美元，市盈率为-3.93倍，贝塔系数为0.18。该公司的负债权益比率为0.40，速动比率为13.41，流动比率为13.41。该公司的50日移动均线切入位在1.92美元，200日移动均线切入位在2.89美元。Candel Treeutics的12个月低点为1.47美元，12个月高位为8.70美元。
Institutional Inflows and Outflows
机构资金流入和流出
About Candel Therapeutics
关于秋茄治疗公司
(Get Rating)
(获取评级)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Candel Treateutics，Inc.是一家临床阶段的生物制药公司，致力于为癌症患者开发免疫疗法。该公司开发了CAN-2409，目前正处于治疗胰腺癌的第二阶段临床试验；治疗前列腺癌的第三阶段临床试验；以及治疗肺癌的第二阶段临床试验，以及治疗高级别胶质瘤的Ib/II阶段临床试验。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- 免费获取StockNews.com关于Candel治疗(CADL)的研究报告
- MarketBeat：回顾一周12/12-12/16
- 哪两家蓝筹科技公司提高了他们的指引？
- 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗？
- 拖拉机库存能否突破杯柄收购点？
- 现在不是购买Lennar的时候，但时机即将到来
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《秋茄治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Candel Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧